Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Sarepta Therapeutics, Inc. - Common Stock (NQ:SRPT)

37.94 +1.51 (+4.14%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 19, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Sarepta Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
21 22 Next >
Sarepta Therapeutics to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference
From Sarepta Therapeutics, Inc.
Via Business Wire
This Early-Stage Biotech Stock Is Up 400% — Should You Buy Now?
Avidity Biosciences' stock has performed incredibly well in 2024. Its Duchenne muscular dystrophy drug is showing strong results in trials. 
Via MarketBeat
How Is The Market Feeling About Sarepta Therapeutics?
Via Benzinga
A Closer Look at 28 Analyst Recommendations For Sarepta Therapeutics
Via Benzinga
$100 Invested In This Stock 10 Years Ago Would Be Worth $600 Today
Via Benzinga
2 Biotech Stocks to Buy Hand Over Fist in August
Both of these biotechs are highly innovative companies. 
Via The Motley Fool
Smart Money Is Betting Big In SRPT Options
Via Benzinga
NASDAQ:SRPT may be ready to breakout.
NASDAQ:SRPT may be ready to breakout. 
Via Chartmill
26 Analysts Have This To Say About Sarepta Therapeutics
Via Benzinga
Warner Bros, Airbnb And Monster Beverage Are Among Top 10 Large Cap Losers Last Week (Aug 4-Aug 10): Are The Others In Your Portfolio?
These 10 stocks had the biggest drop last week, with McKesson Corporation, BIO-TECHNE Corp, and Warner Bros. Discovery, Inc. being the worst performers. 
Via Benzinga
How Avidity Biosciences Just Dropped The Hammer On Sarepta Therapeutics
The company is coming up fast with a platform that could take on several of Sarepta's approved treatments. 
Via Investor's Business Daily
McKesson Reports Weak Sales, Joins JFrog, Fastly, Warner Bros. Discovery And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
Via Benzinga
7 Biotech Stocks to Buy for Their Game-Changing Potential
Although the market may be reeling from the recent fallout, the red ink presents a viable opportunity in these biotech stocks. 
Via InvestorPlace
Here's How Much $1000 Invested In Sarepta Therapeutics 10 Years Ago Would Be Worth Today
Via Benzinga
Here's How Much $100 Invested In Sarepta Therapeutics 10 Years Ago Would Be Worth Today
Via Benzinga
Expert Outlook: Sarepta Therapeutics Through The Eyes Of 25 Analysts
Via Benzinga
Sarepta Therapeutics (SRPT) Q2 2024 Earnings Call Transcript
SRPT earnings call for the period ending June 30, 2024. 
Via The Motley Fool
Topics Earnings
Exposures Financial
SRPT Stock Earnings: Sarepta Therapeutics Beats EPS, Misses Revenue for Q2 2024
SRPT stock results show that Sarepta Therapeutics beat analyst estimates for earnings per share but missed on revenue for the second quarter of 2024. 
Via InvestorPlace
Sarepta Therapeutics Announces Second Quarter 2024 Financial Results and Recent Corporate Developments
From Sarepta Therapeutics, Inc.
Via Business Wire
3 Genomics Stocks That May Transform Personalized Medicine
These are three of the best genomics stocks to buy for a lucrative entry into a specialized section of the biotech industry. 
Via InvestorPlace
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Sarepta Therapeutics, Inc.
Via Business Wire
Looking At Sarepta Therapeutics's Recent Unusual Options Activity
Via Benzinga
Sarepta Therapeutics to Announce Second Quarter 2024 Financial Results
From Sarepta Therapeutics, Inc.
Via Business Wire
SAVA Stock Plunges as Cassava Sciences CEO Steps Down. What to Know.
The CEO of Cassava Sciences is stepping down, effective immediately. Here's what this means for troubled SAVA stock. 
Via InvestorPlace
Jim Cramer Says Don't Sell Match Group: 'You've Just Got A Very, Very Smart Investor In There'
Jim Cramer doesn't favor Fortinet, but owns Palo Alto Networks for charity. Air Products not doing well due to better run company Linde. 
Via Benzinga
Cassava Sciences Announces Changes in Executive Leadership, Enhanced Corporate Governance and Other Initiatives
From Cassava Sciences, Inc.
Via GlobeNewswire
After a Big Win, Is Sarepta Therapeutics Stock a Buy?
One key issue remains unresolved, and it could be a significant one. 
Via The Motley Fool
Has Sarepta Therapeutics Become a No-Brainer Stock Buy After This Recent FDA News?
The label expansion paves the way for much more revenue growth for Sarepta in the years ahead. 
Via The Motley Fool
Exposures Product Safety
1 Soaring Growth Stock to Buy and Hold for 10 Years
Let's look beyond the biotech's performance this year. 
Via The Motley Fool
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Sarepta Therapeutics, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
21 22 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS